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ABSTRACT  
Background: Several pPivotal and post-marketing studies showed demonstrated the  efficacy and 
the good tolerability profile of natalizumab (NTZ) in Multiple Sclerosis (MS) patients. On the other 
hand, long-term safety of natalizumab NTZ therapy is burdened by the risk of progressive 
multifocal leukoencephalopathy, especially in anti-JCV seropositive patients treated for more than 
two 2 years, who sometimes are required. Therefore the need to stop  natalizumab the treatment 
drug aroused, thus disclosing the issue ofat the risk of disease reactivation. Objectives: To evaluate 
the effects of natalizumab discontinuation in a monocentric cohort of MS patients followed for a 
mean time of 22.4 months and to compare the efficacy of different therapeutic strategies in this 
period of time. Methods: One hundred and ten MS patients who stopped NTZ after >12 infusions 
have been followed with periodic clinical and magnetic resonance imaging (MRI) evaluations.One 
hundred and ten patients stopped therapy after at least 12 infusions.. After drug interruption, oOne 
hundred patients of them started either immunomodulant therapy (nN=90) or fingolimod (nN=10), 
while 10 patients didn’t start any treatmentremained without any drugs. We followed them with 
periodic clinical and magnetic resonance imaging (MRI) evaluations. Results: “Disease-activity 
free” patients were 25% at one year after discontinuation, and annualized relapse rate significantly 
increased from 0.06 to 0.84 compared to 0.06 on treatment (p<0.0001). We found that the risk of 
reactivation peaked despite alternative concomitant treatments bBetween the second and the eighth 
month after suspension, a so-called “high risk period”, during which , risk of reactivation peaked 
despite alternative treatments; the majority of patients (xx?) showed a return to pre-natalizumab 
disease activity while and 10% of patients them presented “rebound activity”. A higher pre-
natalizumab disease activity is was correlated with an increased risk of reactivation (p=?).   
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Conclusions: Our data suggest that disease reactivation peaked during a “high risk period” between 
the second and the eighth month since stopping the drug. During this period, no alternative 
concomitant treatments seemed to provide an adequate protection from disease reactivation. Though 
transient, this phase could be potentially dangerous, therefore we need to develop more effective 
better strategies to deal with this challenge. 
INTRODUCTION  
Natalizumab is a monoclonal antibody directed against α4 subunit of integrin expressed on the 
surface of activated T-cells, preventing their transmigration through the blood-brain barrier 
(Chaudhuri et al, 2003). Post-marketing studies have confirmed both short and long term 
persistence of natalizumab efficacy in Multiple Sclerosis (MS) patients (Oturai et al., 2009; Putzki 
et al., 2010). However its profile is burdened with the risk of progressive multifocal 
leukoencephalopathy (PML), especially beyond 24 infusions (Clifford et.al, 2010). Nowadays the 
combination of anamnestic information and the result of anti-JC virus antibodies test allows a better 
assessment of PML risk, towards a more individualized treatment approach. (Sorensen et al., 2012; 
Bloomgren et al., 2012). For this reason,  International Drug Agencies including FDA and EMEA 
recommended to re-evaluate natalizumab the bBenefit-Risk profile after two years of treatment in 
light of the increased risk of PML (puoi dare un link come referenza del documento emesso da 
queste agenize nel quale si precisa questo aspetto). On the other hand, the need to stop natalizumab 
treatment enlightened the risk of disease reactivation. A natalizumab phase II clinical trial already 
showed that the interruption of natalizumab treatment was associated to evidence of radiological 
and clinical activity (Miller et al., 2003). Afterward, some post-marketing studies suggested that 
stopping natalizumab therapy was associated with a rebound of clinical and MRI activity beyond 
the expected disease reactivation level in a significant proportion of patients starting three months 
after the drug interruption (Killestein et al., 2010; Kerbrat er al., 2011; Vellinga et al., 2008; Havla 
et al., 2011). Instead, some other studies showed a substantial return to pre-natalizumab disease 
activity
 (O’Connor et al., 2011; Stüve et al, 2009; Kaufman et al., 2011). Nevertheless, the 
reliability of these observations has been questioned because the majority of these studies consisted 
of small case series and/or short term observations.  
The objective of this monocentric prospective study is to evaluate the effects of natalizumab 
discontinuation in a large cohort of patients with a follow-up of two years. The proportion of 
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patients who presented clinical relapses and/or new or enlarging T2-weighted lesions and/or 
Gadolinium (Gd)-enhancing lesions was assessed. The effect of different alternative therapeutic 
options on the prevention of disease reactivation was also evaluated. 
MATERIAL AND METHODS 
We collected clinical and MRI data of 110 consecutive MS patients, followed as out patients at the 
San Raffaele MS Centre in Milan, who stopped natalizumab after at least one year of therapy. This 
study was planned within a post-marketing program of evaluatingaimed to evalutate the bBenefit-
rRisk profile of natalizumab NTZ treatment. Included patients underwent a mean of 24 ± 10.7 
natalizumab courses (range: 12-57). Demographic and clinical data of patients are shown in Table 
1.  
The mean follow-up after natalizumab discontinuation was 22.4 months (range: 6.3-37.8). 
Reasons for drug discontinuation were: a) a shared decision with the treating neurologist due to 
anti-JC virus seropositivity combined with other risk factors (long treatment duration and/or 
previous use of immunosuppressive treatment) (n=94); b) self decision based on fear of PML 
(n=10) before the availability of anti-JC virus testing; c) pregnancy planning (n=6). Ten patients 
decided on their own to discontinue natalizumab before the availability of anti-JC virus testing for 
fear of PML. Ninety-four patients interrupted natalizumab after a shared doctor-patient choice 
because of anti-JC virus seropositivity combined with other risk factors (long treatment duration 
and/or previous use of immunosuppressive treatment). Additional 6 patients withdrawn therapy due 
to desire of pregnancy.  
After stopping natalizumabNTZ stop, we proposed to all patients the to beginning shift to of an 
alternative therapy to all patients..  For patients who received natalizumab because of a 
breakthrough disease, the choice was based on a shared doctor-patient decision. Ninety patients 
(81.8%) started immunomodulant therapy, either glatiramer acetate (72 patients) or different 
formulations of beta-interferon-beta (18 patients) within approximately one month after last 
natalizumab infusion. The choice between these two first- line treatments was based on which 
treatment the patients did not respond to in the pre-natalizumab period. Ten (9.1%) additional 
patients who discontinued natalizumab started oral therapy with fingolimod after a mean of 4.6 
months (range 3-6), such . This option was being available only sincesince April 2012. The 
remaining 10 patients (9.1%) did not start any disease modifying treatment (6 for desire of 
pregnancy planning and 4 for refusal of injective therapy before the availability of fingolimod 
availability). In order to prevent disease reactivationMoreover, 25 patients (22.7%) underwent 
monthly courses of intravenous (iv) methylprednisolone (1 g for 2 days of 1 gram of ) intravenous 
(i.v.) methylprednisolone starting 2 months after natalizumab discontinuation in addition to disease 
modifying therapies.  
Neurological examinations were performed every three months, or in case of exacerbation. Most 
pPatients underwent brain MRI scans approximately at the 3rd (± 1), 6th (± 1) and 12th month (+3) 
after natalizumab interruption. Additional MRI scans were sometime have been performed in case 
of if a relapse occurrenced. One hundred patients (91.1%) underwent the 3rd month brain MRI and 
80 (72.7%) the 6th month scan; all patients had at least one MRI in the first six months after 
natalizumab NTZ discontinuation. Moreover, 74 patients (67.2%) had a brain MRI at one year after 
discontinuationdrug stop. We considered defined new or enlarging T2-weighted lesions and/or 
Gadolinium (Gd)-enhancing lesions as active scans those with new or enlarging T2-weighted 
lesions and/or Gadolinium (Gd)-enhancing lesions. Patients were classified as “disease activity 
free” if the absence of relapses was combined with the absence of active scans and disease 
progression. Disease progression was defined as an increase of Expanded Disability Status Scale 
(EDSS) of 1.0 point on the Expanded Disability Status Scale (EDSS) for patients with baseline 
EDSS < or = 5.5 and of 0.5 point for baseline EDSS > or = 6.0. Patients were classified as “disease 
activity free” if the absence of relapses was combined with the absence of active scans and disease 
progression. 
Based on the pre-natalizumab radiological and clinical features of the disease activity before NTZ 
start, we divided our cohort of patients in two subgroups, named “highly active” and “lowly active”. 
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We classified our patients as “highly active” if they presented an annualized relapse rate (ARR) ≥ 3 
in the year prior to natalizumab and/or ≥ 4 gadolinium-enhancing lesions at baseline brain MRI. 
The remaining patients were defined as “lowly active”. 
We also tried to identify patients who presented the conventionally called “rebound activity”, 
during in which the severity of relapses and/or the number of new T2 or Gd-enhancing lesions was 
much higher than the  pre-natalizumab activity. Literature lacks of a clear and univocal definition of 
“rebound activity”, therefore we opted decided to perform a for a case by case review case by case 
of disease activity by MS-expert neurologists (metti le iniziali fra parentesi). We arbitrarily decided 
to classify patients as rebound activity having Selected patients presented at least one of the 
following features: a) a clinically significant increase of relapse rate in comparison to pre-
natalizumab disease course (cosa intendi?); b) one or more severe relapses with sustained disability 
progression; c) 5 or more new large T2 lesions and/or at least 10 more Gd-enhancing lesions than 
pre-natalizumab baseline scan. 
T-test was used to compare parametric variables and Mann-Whitney test for non-parametric 
valuesones. Kaplan-Meier curves were built to evaluate the proportion of patients free from 
relapses, MRI activity or combined disease activity at different time-points. We compared survival 
curves by performing the log-rank (Mantel-Cox) test. 
Local Ethical Committee approval was obtained before data collection.  
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RESULTS 
The proportion of patients who was relapse free during the follow up was 83% at 3rd month, 60% at 
6th month and 44% at one year (figure 1 a). Half of the patients presented a relapse within 10 
months after last natalizumab infusion (median survival time of 9.77 months). The ARR in the first 
year after natalizumab NTZ discontinuation significantly increased to 0.84 compared to 0.06 
observed on during the NTZ treatment (p<0.0001).  
The risk of rRelapse frequencys in the entire population had a peaked at in the 4th month, remained 
high until the 98th month and then returned to a level similar to the one observed during 
natalizumab treatment declined at the end of the first year after discontinuation to a value close to 
that observed during natalizumab treatment (figure 2).  
Similarly, aAt one- year follow-up the mean median Expanded Disability Status Scale (EDSS) 
significantly increased from xx to 3.0 (p<0.001). Specifically , and 16 patients (14.5% of the total), 
who had a baseline EDSS >3.0 at the time of NTZ discontinuation,.experienced aas a result of 
relapses a sustained progression was observed in 16 patients (14.5% of the whole cohort), especially 
in the subgroup of patients with a baseline EDSS equal or greater than 3.0. of disability after NTZ 
stop.  
The proportion of patients “free from MRI activity” was 85% at 3rd month 3, 54% at 6th month 6 
and 35% at one year (figure 1 b). The mean number of Gd-enhancing lesions increased from 1.46 at 
the 3rd month 3 to 3.07 at the 6th month 6 and then declined to 1.700 at one year, compared to xx 
during NTZ treatment.  
The proportion of “disease-activity free” patients was 75% at 3rd month 3, 42% at 6th month 6 and 
25% at one year (figure 1 c). The risk of disease reactivation was higher between the second and the 
eighth month after natalizumab suspension. Toglierei la frase in rosso: è già stata detta piu’ volte. 
Beyond this time-point the slop reducedAfter 1-year of follow-up, the proportion of disease activity 
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free patients did not substantially change (even prolonging the time of observation up to 25 months 
for patients who remained in immunomodulatory treatment (survival proportion of 18.4% at 25-
month follow-up). 
Patients who received an alternative disease modifying therapy after natalizumab discontinuation 
had a significantly higher probability to remain “disease-activity free” compared to untreated 
patients (30% versus 0% at 1-one year f-up after NTZ discontinuation). On the contrary, the type of 
treatmentdrug , whether immunomodulants like IFN or GA (IM) or fingolimod (FTY), had no 
effects impact on the condition proportion of disease activity free patients (p=) (figure 3). In 
particular, a disease reactivation was observed in 6 out of the /10 patients who started fingolimod 
treatment and in xx/xx who began immunomodulant ones (p=). Moreover, we did not find any 
evidence of disease activity reduction in tThe 25 patients who received preventive steroid courses 
monthly i.v. methylprednisolone cycles after NTZ treatment compared to those who did not receive 
them (p=)did not show a significant lower level of MS activity if compared to patients who did not 
receive preventive steroid courses. 
Twenty-five (34%) of 73 patients showing disease reactivation during immunomodulante 
treatmentsunder IM therapy in the first year after NTZ stop shifted to second-line therapies within 3 
months after relapse and/or active MRI occurrence. Specifically 16 returned to natalizumab and 9 
started other alternative second-line therapies (i.e. fingolimod, nN=7;, or i.v. immunosuppression 
with pulsed cyclophosphamide immunosuppression,, Nn=2). We compared these two groups of 
patients with 48 patients who did not change disease modifying therapy. At a mean follow- up of 17 
months we found a significant lower risk of persistentreduction of frequency of disease activity in 
the those who returned to natalizumab groupNTZ (p< 0,05), while there was no apparent advantage 
in shifting to other second-line therapies (p=ns), even if data were inflated by a small sample size.; 
these data are probably affected by the small number of patients included in this analysis. Overall 
the risk of disease reactivation after NTZ stop was statistically correlatedincreased in patients both 
with a higher ARR in the last year before starting natalizumabNTZ start (2.08 in reactivated patients 
versus 1.54 in stable patientsones;, p<0.005) and in those with a higher mean number of enhancing 
lesions in the pre-treatment brain MRI (2.60 versus 1.08;, p<0.03704). Moreover, patients defined 
as “highly active” in the year prior to natalizumab (ARR ≥ 3 and/ or ≥ 4 gadolinium-enhancing 
lesions at baseline brain MRI) had a higher risk of disease reactivation (xx vs xxx; p=0.004); (figure 
4). 
Finally we compared clinical and radiological disease activity in the period after NTZ stop with the 
one in the reactivation after discontinuation to disease activity in the year before starting 
natalizumab. Post-natalizumab NTZ ARR was significantly lower than pre-natalizumab ARRNTZ 
one (1.98 versus 0.84;, p<0.05). However it is interesting to note that the mean number of Gd-
enhancing lesions at the 6th month after discontinuation was significantly higher than the number 
observed at the beginning of natalizumab treatment (3.07 versus 2.24;, p<0.001).  
Moreover we identified 11 patients (10%) who presented the conventionally called rebound activity 
in which the severity of relapses and/or the number of new T2 or Gd-enhancing lesions was much 
higher than pre-natalizumab activity. Specifically, 4 patients had both either clinical and neuro-
radiological severe reactivation, whereas 5 patients showed only a remarkable MRI rebound 
activity, and remaining . The last two patients experienced had a very disabling relapse with only a 
few enhancing lesions probably because MRI scan was performed after i.v. steroid therapy. 
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DISCUSSION 
Since natalizumab safety profile forces demands to cautiouslya cautious evaluation of itse long-term 
treatmentuse, concerns on disease reactivation after natalizumab suspension were addressed in 
many reports. Altogether available data confirm that disease stability, reached during natalizumab 
therapy, does not continue after treatment discontinuation, since the drug does not cause long-term 
immunological changes. 
Our study is the result of everyday clinical practice and wasa real world study conducted in one of 
the largest monocentric cohort  of MS patients stopping natalizumab with a 1-year follow-up,. 
Moreover patients were followed for more than a year thus providing long term data on disease 
course after withdrawal from natalizumab withdrawal. These strengths could at least partially 
compensate the expected bias of every nonrandomised study conducted in the clinical setting. Till 
now, a part from many several observational studies with smaller cohorts than ours (references?), 
there is only one ongoing clinical trial (RESTORE) which that compares patients continuing 
natalizumab with patients those receiving using placebo or an alternative treatment (glatiramer 
acetateGA, beta-interferonIFN-beta or IV iv steroids according to neurologists’ choice). Preliminary 
data of this trial showed a proportion of disease reactivation of about 50% seven months after 
withdrawal from natalizumab, with no significant differences between either in the placebo or inand 
the alternative treatment group
 
arm
 
(Kaufman et al., 2012). 
Our data showIn this papr we show that only a quarter 25% of our patients remained “disease-
activity free” one year after discontinuation. As It is known in from the literature that the 
concentration of, natalizumab concentrationNTZ progressively decrease within 3 months, whereas 
changes induced on the immune system could be detected until 6 months after discontinuation
 
(Stüve et al, 2006). Accordingly we found a peak of the risk of relapse risk in the at the 4th th 
month after discontinuation, and thisthe risk is stillbeing high untilat the 8th month 8 and 
decreasing at 1-year follow-upwhile after one year it returns to a lower value. Similarly we have the 
maximum number ofalso gGd-enhancing lesions at MRI scans performed were more frequent at the 
6th month period after NTZ suspensionstop, being. The mean number of enhancing lesions at this 
time point is significantly higher even if compared to brain scans performedthan in the period 
before the beginning of natalizumab therapyNTZ start. Our study confirmed literature data since the 
majority of our patients showed a substantial return to their pre-natalizumab disease activity 
(references?). However according to clinical and radiological data only 10% of our cohort presented 
the so- called rebound activity. Interestingly disease reactivation was observed mostly during a 
“high risk period” between the second and the eighth month after drug discontinuation. Then, after 
this period, we observed a reduction in the slop of the survival curve of disease activity, as well as a 
decline of relapse risk and of the mean number of Gd-enhancing lesions (figure 1 and 3). 
Higher ARR and mean higher enhancing lesions in the year before natalizumab were identified as 
predictive factors associated to an increased risk of disease recurrence. Likewise O’Connor found 
that patients enrolled inof registrative registered trials with a higher level of prior-to-natalizumab 
disease activity tended to have a higher ARR after discontinuation (O’Connor et al., 2011). 
Our study was also aimed to evaluate the effects of starting an alternative treatment soon after 
natalizumab interruption. According to our analysis, first-line immunomodulants can reduce the 
degree of reactivation after natalizumab discontinuation only in a subgroup of patientshowever they 
fail to prevent it in most of the patients. These findings are consistent with data published by 
O’Connor (O’Connor et al., 2011) and Cohen (Cohen M et al., 2013) who observed a return of MS 
activity regardless the beginning of preventive therapy after natalizumab suspensionstop. Moreover 
we did not observe a statistically significant effect of doses of i.v. methylprednisoloneintravenous 
steroid cycles in preventing MS reactivation as reported in another survey (Borriello et al., 2012). 
Considering that seventy-five percent of our cohort showed signs of disease reactivation after NTZ 
discontinuation, patients should be closely monitored  to detect clinical and/or radiological disease 
activity as soon as possible in order to readily change preventive therapy or, even going backto 
return to natalizumab therapy despite PML risk. A strict clinical observation is even more important 
for patients with residual disability after relapse occurrenceconsidering that relapses might result in 
a sustained progression.  
Moreover, given that a higher pre-natalizumab disease activity seems to be a factor predicting 
reactivation, a careful evaluation of single-patient bBenefit-rRisk ratio is mandatory when stopping 
natalizumab. Patients at risk of developing PML have also toshould be stratified according to MS 
their own disease history, i.e. clinical characteristics before starting natalizumabNTZ start, as well 
as and to residual therapeutic options and , as well as possible contraindications to other therapies. 
Due to delays in the authorization of fingolimod approval in Italy, only a very small proportion of 
our patients started the an oral drug after natalizumab discontinuation, therefore we cannot give 
indication on its efficacy in preventing reactivation. The lack of difference of efficacy between 
fingolimod and apparent similarity of behavior with immunomodulants as shift therapy that we 
observed in our study could be just a statistical bias due toartifact determined by the small sample 
size. Therefore, mMore data are needed to determine if fingolimod could be a feasible therapeutic 
option just after natalizumab, even if it is worthwhile to mention that first reports in literature show 
disease reactivation was detected in half of the patients shifting to oral therapy by an Italian group 
(Rinaldi et al., 2012). More rRecently, in a cohort of MS patients recruited for a safety study, those 
who started fingolimod after natalizumab discontinuation showed a low risk of relapses (aggiungi I 
numeri). Nevertheless this risk is was 3-fold higher in patients starting fingolimod 3-6 months after 
natalizumab compared with to naive patients who never received natalizumab (Comi et al., 2013). 
 
 
 
 
  
 
 
 
CONCLUSIONS  
In our cohortthis cross-sectional study, 3 out of 4 patients presented disease reactivation despite the 
starting beginning of an alternative treatment after natalizumab discontinuation. This observation 
suggests that at least between the second and the eighth month after the last dose, the so called 
“high risk period”, neitheror immunomodulants nor fingolimod provide an adequate protection from 
disease reactivation. This phase, though transient, could be potentially dangerous, since 14.5% of 
our patients showed sustained progression as a result of relapses; therefore, we need to develop 
better more effective strategies to deal with such athis challenge. Frequent Serial MRI evaluations 
in the first 6-8 months after discontinuation mightay help to detect patients with strong disease 
reactivation. In these patients, a more aggressive approach, such as an immunosuppressive 
treatment with i.v. pulsed cyclophosphamide, could be attempted. Finally in patients with lower risk 
of PML the opportunity to restart natalizumab should also be considered in combination with close 
clinical and MRI monitoring. 
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FIGURE  
 
Figure 1. Panel a. Survival curve of relapse-s free patients. Number of patients available for analysis 
(patients), number of observed events (events) and proportion of “relapse free” patients (surviving 
rate) are written under major time-points. Panel b. Survival curve of MRI activity- free patients. 
Number of patients available for analysis (patients), number of observed events (events) and 
proportion of “MRI activity- free” patients (surviving rate) patients are written under major time-
points. Panel c. Survival curve of disease activity- free patients. Number of patients available for 
analysis (patients), number of observed events (events) and proportion of MRI activity-free patients 
(surviving rate) are written under major time-points. Number of patients available for analysis, 
number of observed events and proportion of “disease activity free” patients are written under major 
time-points. In all panels, the xX aAxis shows refers to the months after natalizumab NTZ 
discontinuation. 
 
Figure 2. Annualized relapse rate (ARR) taken at during different time points intervals after 
natalizumab discontinuation. ARR peaks at 4-6 months, then it progressively decrease. The x axis 
refers to the months after NTZ discontinuation. 
Io aggiungerei anche il livello di ricadute durante il trattamento con NTZ (puoi mettere solo un 
punto: NTZ treatment). 
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Figure 3. Survival curvesanalysis of disease activity- free patients after natalizumab NTZ 
discontinuation comparing untreated patients (UN; dashed line),  and patientsthose who receiving 
received either immunomodulant therapy (IMs; dotted line) and thoseor who were treated with 
fingolimod (FTY; continuous line). The xX aAxis shows the months after  natalizumab 
discontinuation. P values refer to the log-rank test (aggiungi I p-values). 
 
 
 
Figure 4. Survival curves analysis of disease activity-free patients free from disease activity after 
natalizumab NTZ discontinuation comparing a group of pre-natalizumab “highly active” patients 
(HA; continuous line) and a group of pre-natalizumab “lowly active” patients (LA; dashed line). 
The x axis shows the months after natalizumab discontinuation.  
The p value refers to the log-rank test. 
Difference observed is statistically significant (p=0.004). X Axis shows months after natalizumab 
discontinuation.  
  
